Clinical Oncology: Case ReportsJournal of Oncology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Utilization of Dual Immunotherapy for Metastatic Pulmonary Pleomorphic Giant Cell Carcinoma: A Case Report

Introduction: Pulmonary Pleomorphic Carcinomas (PPC) are a rare histologic subgroup of sarcomatoid Non-Small Cell Lung Carcinomas (NSCLC). They are characterized by more aggressive growth and elicit a poorer response to antitumor chemotherapy. Furthermore, PPC is associated with an increased likelihood of early metastasis as well as a high risk of relapse. Here, we report the clinical course of a patient with PPC treated with dual immune checkpoint inhibitor therapy and highlight the partial response observed with this approach.

Case Presentation: A 48-year-old male presented with metastatic high-grade pleomorphic giant cell carcinoma.

The liquid biopsy from the original brain lesion revealed no actionable mutations. Next generation sequencing results showed PD-L1 50% and Tumor Mutational Burden (TMB) of 13 mutations per megabase. He was initiated on nivolumab 3 milligrams (mg)/kilogram (kg) every 2 weeks and ipilimumab 1 mg/kg every 6 weeks in a 42-day cycle. He also underwent Stereotactic Radiosurgery (SRS) to the brain lesions. After completing two cycles of treatment, his repeat PET scan showed an overall interval partial response.

Conclusion: Dual immune-checkpoint inhibitor therapy is effective for the treatment of PPC and prospective clinical trials are warranted.

Special Features

Full Text


Track Your Manuscript

Media Partners